MRKR

Business Context and Reporting Period

Company: Marker Therapeutics, Inc. (MRKR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Marker is a clinical-stage immuno-oncology company developing non-genetically engineered Multi Antigen Recognizing (MAR)-T cell therapies. The company focuses on two primary product candidates: MT-601 (autologous for lymphoma and pancreatic cancer) and MT-401-OTS (off-the-shelf for Acute Myeloid Leukemia and Myelodysplastic Syndromes). The company does not currently have any approved products or commercial revenue.

Key Financial Metrics

Note: The company reported no commercial product revenue. All revenue is derived from government and foundation grants.

Material Changes vs. Prior Period

• Revenue Growth: Grant income increased 99% to $6.59 million, driven by new awards from CPRIT, NIH, and SBIR programs.
• Expense Shifts: Research and Development (R&D) expenses increased 29% to $13.47 million, primarily due to a $4.5 million increase in outsourced manufacturing costs from Cell Ready. Conversely, General and Administrative (G&A) expenses decreased 43% to $4.24 million due to headcount reductions and lower professional fees.
• Manufacturing Strategy: The company sold its in-house manufacturing facilities to Cell Ready in 2023 (classified as discontinued operations). In 2024, it operated under a Master Services Agreement (MSA) with Cell Ready, which was subsequently terminated in March 2025.
• Capital Raise: In December 2024, the company completed a private placement raising approximately $16.1 million in gross proceeds (net proceeds ~$14.9 million) through the sale of common stock, pre-funded warrants, and private placement warrants.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Based on current cash levels and burn rate, the company expects to fund operations into the first quarter of 2026, assuming no additional grant funds are received.
• Clinical Progress:
  • MT-601 (Lymphoma): Phase 1 APOLLO study data (cutoff Sept 2024) showed a 78% objective response rate in the first cohort, with 44.4% achieving complete response. No dose-limiting toxicities were reported.
  • MT-601 (Pancreatic Cancer): Received a $9.5 million CPRIT grant to support clinical investigation.
  • MT-401-OTS: The company is prioritizing the Off-the-Shelf program for AML/MDS, with plans to dose the first patient in the second half of 2025.
• Manufacturing Risks: The termination of the MSA with Cell Ready in March 2025 creates uncertainty regarding future manufacturing supply. The company is currently evaluating new third-party CDMO partners for pivotal trials planned for 2026.
• Regulatory Risks: As a clinical-stage company with no approved products, the company faces significant risks related to clinical trial outcomes, regulatory approval timelines, and the ability to secure future funding.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "first quarter of 2026" liquidity estimate given the termination of the Cell Ready MSA and potential delays in securing new manufacturing partners.
• Manufacturing Transition: Confirm the status of negotiations with new CDMO partners to ensure clinical supply for the pivotal lymphoma trial scheduled for 2026.
• Grant Receivables: Review the collectability of the $2.1 million in grant income receivables (primarily from CPRIT) recorded on the balance sheet.
• Dilution Risk: Assess the impact of outstanding warrants (approx. 8.3 million shares) and the recent private placement on future shareholder dilution.
• Clinical Data Durability: Monitor long-term follow-up data from the MT-601 APOLLO study to validate the durability of the reported complete responses.